SG3 Management’s Altimmune ALT Stock Holding History

SG3 Management’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-3,000	Closed	-$36.5K	–	964
2021 Q2	$30K	Buy	3,000 +500	+20%	+$6.84K	﹤0.01%	954
2021 Q1	$35K	Buy	+2,500	New	+$40.4K	﹤0.01%	1104

Other funds holding ALT

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

SG3 Management's ALT Position: Q3 2021 in Review

SG3 Management sold out of Altimmune (ALT) in Q3 2021, closing a stake of 3,000 shares — an estimated $36.5K sold.

SG3 Management first reported a position in ALT in Q1 2021 and held it in 2 quarters. The position peaked at $35K in Q1 2021. 118 funds tracked by Wall St. Rank hold ALT as of Q3 2021.

SG3 Management reported no remaining Altimmune position as of Q3 2021 after selling out during the quarter.
SG3 Management sold 3,000 Altimmune shares in Q3 2021, an estimated $36.5K.
SG3 Management first reported a position in Altimmune in Q1 2021 and held it in 2 quarters.
SG3 Management's Altimmune position peaked at $35K in Q1 2021.
118 funds tracked by Wall St. Rank held Altimmune as of Q3 2021.

Based on SG3 Management's 13F filing for Q3 2021, filed 15 Nov 2021.